Apixaban versus Warfarin in Patients with Atrial Fibrillation

Abstract

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).

Keywords

Affiliated Institutions

• Goethe University Frankfurt DE
• University of Missouri Health System US
• Carmel Medical Center IL
• University of New Mexico US
• St.John's Medical College Hospital IN
• Tokai University JP
• OLVG NL
• Instituto Nacional de Cardiología MX
• Instituto Dante Pazzanese de Cardiologia BR
• University Hospital in Motol CZ
• Fu Wai Hospital CN
• University Medical Center US
• Oslo University Hospital
• Clinical Research Institute US
• Bristol-Myers Squibb (United States) US
• Hospital Universitario La Paz ES
• Duke Medical Center US
• The University of Adelaide AU
• Lenox Hill Hospital US
• Uppsala University SE
• University of California, San Francisco US
• Mayo Clinic in Arizona US
• Estudios Clínicos Latinoamérica AR
• Institute of Experimental Cardiology RU
• Chinese Academy of Medical Sciences & Peking Union Medical College CN
• University of Alberta CA

Related Publications